Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.

Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.

Apr 16, 2025

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Big Pharma Giant Johnson & Johnson Reports Earnings That Beating Wall Street

Apr 15, 2025

CSRXP STATEMENT ON U.S. SENATE AND U.S. HOUSE REINTRODUCTION OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION, LOWER DRUG PRICES

Lawmakers Should Advance Bipartisan Solution to Crack Down on Anti-Competitive Big

Apr 7, 2025

THEY SAID IT! SENATE JUDICIARY CALLS OUT BIG PHARMA’S ANTI-COMPETITIVE PRACTICES THAT KEEP PRESCRIPTION DRUG PRICES HIGH

Senators on Both Sides of the Aisle Highlight Concerns with Big Pharma’s Patent Abuse,

Apr 3, 2025

CSRxP STATEMENT ON SENATE JUDICIARY PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES

Committee Markup Advances Legislation to Crack Down on Big Pharma’s Anti-Competitive

Apr 16, 2025

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Big Pharma Giant Johnson & Johnson Reports Earnings That Beating Wall Street

Apr 15, 2025

CSRXP STATEMENT ON U.S. SENATE AND U.S. HOUSE REINTRODUCTION OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION, LOWER DRUG PRICES

Lawmakers Should Advance Bipartisan Solution to Crack Down on Anti-Competitive Big

Apr 7, 2025

THEY SAID IT! SENATE JUDICIARY CALLS OUT BIG PHARMA’S ANTI-COMPETITIVE PRACTICES THAT KEEP PRESCRIPTION DRUG PRICES HIGH

Senators on Both Sides of the Aisle Highlight Concerns with Big Pharma’s Patent Abuse,

Apr 3, 2025

CSRxP STATEMENT ON SENATE JUDICIARY PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES

Committee Markup Advances Legislation to Crack Down on Big Pharma’s Anti-Competitive

Videos

Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.

Fact Sheets

Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.

Infographics

Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.

Polling

See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.

Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.

By signing your name, you are opting-in to receive calls and SMS/MMS messages, including autodialed and automated calls and texts, to that number from CSRxP. Msg & data rates may apply.
This field is for validation purposes and should be left unchanged.